Dompe S.p.a.

Farmitalia Carlo Erba S.r.l.

Pharmacia & Upjohn S.p.a.

Paolo Comoglio

Gianfranco Caselli

Carola Ponzetto

Enzo Medico

Paolo Michieli

Carlo Battistini

Alberto Bardelli

Patrizia Giordano

Tiziana Crepaldi

Fabio Corradi

Chiara Collesi

Chiara Colessi

Sabrina De Rosa

Alessandro Vercelli

Francesco Galimi

Maria Cristina Stella

Maria Prat

Recombinant proteins derived by recombination of structural domains obtained from alpha and beta subunits of HGF and/or MSP growth factors. These recombinant proteins contain domains selected from HGF and MSP, and are useful to protect cells, including differentiated cell elements of liver, kidney, and mucosa of the gastorenteral tract, from death (i.e., apoptosis) induced by chemotherapeutics.

Recombinant proteins from HGF and MSP

Recombinant proteins deriving from recombination of structural domains deriving from the &agr; subunits of HGF and/or MSP growth factors. The recombinant proteins of the present invention have biological activity, and protect cells from death (apoptosis) induced by chemotherapeutic drugs. These molecules can conveninently be used to prevent or to treat the toxic side effects of chemotherapeutic agents used in cancer therapy.

Recombinant proteins derived from HGF and MSP

The present invention relates to peptides and peptidomimetic compounds and pharmaceutical compositions containing them as useful pharmacological agents in the control or treatment of proliferative diseases such as cancer, against tumor growing and/or tumoral metastasis, and psoriasis and in the control or treatment of inflammatory, allergic, autoimmune, viral, and cardiovascular diseases. These new compounds have the unique property to inhibit the recognition of several phosphotyrosine containing motifs within all the cellular receptors and cytosolic transducers by a wide spectrum of SH2 domains contained in cytosolic transducers and other effector proteins laying along different pathways of the signal transduction process and with a particularly high affinity for the SH2 domain of the adaptor transducer Grb2, a key element along the pathway to mitogenesis and motogenesis, this last activity leading to invasiveness and to metastasis. The invention also relates to methods for production of the compounds and methods of treatment employing the compounds.

Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use

The present invention refers to the use of Macrophage Stimulating Protein (MSP) for the preparation of a medicament for the treatment of pathologies of the central and peripheral nervous system of traumatic, infectious or inflammatory origin.

Macrophage stimulating protein for the treatment of pathologies of the

Hepatocyte growth factor--induced proliferation and differentiation of

The invention in the field of cell biology relates to novel peptides able to interact with intracellular signal transducers, thus interfering with signal transduction pathways leading to cell proliferation and motility. The peptides of the invention may be chemically synthesized from single amino acids and/or preformed peptides of two or more amino acid residues. The peptides of the invention find an useful application in the treatment of a neoplastic disease.

Peptide inhibitors of mitogenesis and motogenesis

A protein, which is useful as an antagonist of hepatocyte growth factor, is composed of two disulphide-linked chains of 50 kDa and 75 or 85 kDa respectively, the 5 kDa chain being the .alpha.-chain of the tyrosine kinase encoded by the MET protooncogene and the 75 or 85 kDa chain being a C-terminal truncated form of the .beta.-chain of the said tyrosine kinase.

Truncated forms of the hepatocyte growth factor (HGF) receptor

Growing community of inventors

Turin, Italy

Paolo Comoglio